Company Encyclopedia
View More
name
Praxis Precision Medicines
PRAX.US
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance. The company’s platforms include cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and solidus to discover and develop antisense oligonucleotide. It also develops Ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase 3 clinical trial for the treatment of essential tremor; Vormatrigine, a small molecule targeting the hyperexcitable state of sodium-channels in the brain to treat focal onset epilepsy; Relutrigine for the treatment of developmental and epileptic encephalopathies; PRAX-020 to treat KCNT1; and PRAX-050. In addition, the company develops Elsunersen, a clinical-stage ASO designed to regulate NaV1.2 expression for the treatment of SCN2A-DEE; PRAX-080 that targets PCDH19-related developmental epilepsy; PRAX-090 for targeting SYNGAP1 loss-of-function; and PRAX-100 that targets SCN2A LoF mutations.
1.945 T
PRAX.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
BiotechnologyIndustry
Industry Ranking71/394
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-75.20%E
    • Profit Margin-3658.53%E
    • Gross Margin0.00%E
  • Growth ScoreB
    • Revenue YoY364.98%A
    • Net Profit YoY-80.80%E
    • Total Assets YoY-4.77%D
    • Net Assets YoY-10.23%D
  • Cash ScoreB
    • Cash Flow Margin-2.73%D
    • OCF YoY364.98%A
  • Operating ScoreE
    • Turnover0.02E
  • Debt ScoreA
    • Gearing Ratio13.34%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    BUZZ-Praxis jumps on positive meeting with FDA for tremor drug, epilepsy trial success

    Praxis Precision Medicines shares surged 36% after the FDA agreed on a New Drug Application for its tremor drug, ulixacaltamide. The company also reported positive interim results for its epilepsy treatment, relutrigine. Jefferies estimates peak sales could exceed $2.5 billion, with potential NDA acceptance and approval in 2026. The stock is up ~235% YTD.

    Reuters·
    US
    PRAX
    +30.54%
    Reuters·
    US
    PRAX
    +30.54%

    Oil prices rise; Domo shares fall. U.S. stocks up, Nasdaq gains 0.2%. Dow at 47,933.71, Nasdaq at 23,543.03, S&P 500 at 6,867.40. Communication services up 0.9%.Utilities down 0.6%. U.S. PCE price index rose 0.3% in September. Praxis Precision Medicines Inc soared 31%.

    U.S. stocks rose with the Nasdaq up 0.2%, Dow at 47,933.71, and S&P 500 at 6,867.40. Communication services gained 0.9%, while utilities fell 0.6%. The U.S. PCE price index increased by 0.3% in September. Praxis Precision Medicines Inc's shares soared 31% after a successful pre-NDA meeting with the FDA.

    Unusual Whales·
    US
    PRAX
    +30.54%
    Unusual Whales·
    US
    PRAX
    +30.54%

    Crude Oil Moves Higher; Domo Shares Plunge

    U.S. stocks rose slightly on Friday, with Nasdaq up 0.2%. Crude oil increased by 0.7%. Domo shares fell 23% after weak Q3 results. Praxis Precision Medicines surged 31% post-FDA meeting. DigitalBridge shares jumped 32% on SoftBank acquisition talks. Rubrik shares rose 23% after strong Q3 results. U.S. PCE price index and personal spending increased 0.3% in September. European shares mostly fell, while Asian markets were mixed.

    fidelity·
    US
    DBRG
    +45.27%
    US
    DOMO
    -23.64%
    US
    PRAX
    +30.54%
    fidelity·
    US
    DBRG
    +45.27%
    US
    DOMO
    -23.64%
    US
    PRAX
    +30.54%

    U.S. Stock Market Midday Update: Praxis Precision Medicines up 39.39%, driven by FDA meeting and positive research results

    Praxis Precision Medicines rose 39.39%; Precision Science fell 0.02%, with a trading volume of USD 70.38 million; Capricor Therapeutics rose 7.33%, with a trading volume of USD 61.9 million; Amgen fell 0.41%, with a trading volume of USD 32.96 million; AbbVie fell 0.15%, with a market capitalization of USD 403.9 billion

    Tracking Unusual Activity·
    US
    PRAX
    +30.54%
    Tracking Unusual Activity·
    US
    PRAX
    +30.54%

    Praxis Precision Medicines rises 30% to a 3-year high after halting epilepsy study early for strong results.

    Shares of Praxis Precision Medicines soared on Friday after the company decided to end an epilepsy study ahead of schedule due to significant effectiveness. The stock surged 30%, reaching a new three-year high, following this unexpected success in the epilepsy treatment.

    Unusual Whales·
    US
    PRAX
    +30.54%
    Unusual Whales·
    US
    PRAX
    +30.54%
    © 2025 Longbridge｜Disclaimer